The OPTIMA study: Assessing a new cincalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 1, 2008, Pages 36-45

  Messa, Piergiorgio ^a   Macário, Fernando ^b   Yaqoob, Magdi ^c   Bouman, Koen ^d   Braun, Johann ^e   von Albertini, Beat ^f   Brink, Hans ^g   Maduell, Francisco ^h   Graf, Helmut ⁱ   Frazão, João M ^j   Bos, Willem Jan ^k   Torregrosa, Vicente ^l   Saha, Heikki ^m   Reichel, Helmut ⁿ   Wilkie, Martin ^o   Zani, Valter J ^p   Molemans, Bart ^p   Carter, Dave ^p   Locatelli, Francesco ^q  

^a Nephrology Division   (Italy)

^b Dialave   (Portugal)

^c ROYAL LONDON HOSPITAL   (United Kingdom)

^d ZiekenhuisNetwerk Antwerpen   (Belgium)

^e KFH Nürnberg Kuratorium für Dialyse und Nierentransplantation E V   (Germany)

^f Centre de Dialyse Cecil   (Switzerland)

^g MEDISCH SPECTRUM TWENTE   (Netherlands)

^h HOSPITAL GENERAL DE CASTELLÓN   (Spain)

ⁱ Krankenanstalt Stadt Wien R   (Austria)

^j UNIVERSITY OF PORTO   (Portugal)

^k ST ANTONIUS HOSPITAL   (Netherlands)

^l HOSPITAL CLÍNIC   (Spain)

^m TAMPERE UNIVERSITY HOSPITAL   (Finland)

ⁿ UNIVERSITY OF HEIDELBERG   (Germany)

^o SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^p AMGEN INC   (United States)

^q A MANZONI HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CHELATING AGENT; CINACALCET; NAPHTHALENE DERIVATIVE; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D;

ADULT; AGED; ALGORITHM; ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CALCIUM; CHELATING AGENTS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; TREATMENT OUTCOME; VITAMIN D;

EID: 38749101028     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03591006     Document Type: Article

References (32)

1. Martinez I, Saracho R, Montenegro J, Liach F: The importance of dietary calcium and phosphorus in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 29: 496-502, 1997
2. Slatopolsky E, Brown A, Dusso A: Pathogenesis of secondary hyperparathyroidism. Kidney Int 56[Suppl 73]: S14-S19, 1999
3. Salem MM: Hyperparathyroidism in the dialysis population: a survey of 612 patients. Am J Kidney Dis 29: 862-865, 1997
4. Billa V, Zhong A, Bargman J, Vas S, Wong PY, Oreopoulos DG: High prevalence of hyperparathyroidism among peritoneal dialysis patients: A review of 176 patients. Perit Dial Int 20: 315-321, 2000
5. Hruska KA, Teitelbaum SL: Renal osteodystrophy. N Engl J Med 333: 166-174, 1995
6. Spasovski GB, Bervets ARJ, Behets GJS, Ivanovski N, Sikole A, Dams G, Couttenye MM, De Broe ME, D'Haese PC: Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dial Transplant 18: 1159-1166, 2003
7. Rostand SG, Drueke TB: Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56: 383-392, 1999
8. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998
9. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum P04, CaXPO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138, 2001
10. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18: 1731-1740, 2003
11. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
12. Eknoyan G, Levin A, Levin N: K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am I Kidney Dis 42[Suppl 31: S1-S201, 2003
13. Moe S, Drueke TB: Management of secondary hyperparathyroidism: The importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol 23: 369-379, 2003
14. Block GA, Port FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 35: 1226-1237, 2000
15. Johnson CA, McCarthy J, Bailie GR, Deane J, Smith S: Analysis of renal bone disease treatment in dialysis patients. Am J Kidney Dis 39: 1270-1277, 2002
16. Goodman WG: Recent developments in the management of secondary hyperparathyroidism. Kidney Int 59: 1187-1201, 2001
17. Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, Salusky IB: Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46: 1160-1166, 1994
18. Martin KJ, Gonzalez EA: Vitamin D analogues for the management of secondary hyperparathyroidism. Am J Kidney Dis 38[Suppl 5]: S34-S40, 2001
19. Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW: A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58: 436-445, 2000
20. Quarles LD: Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues. Curr Opin Nephrol Hypertens 12: 349-355, 2003
21. Drueke TB: Modulation and action of the calcium-sensing receptor. Nephrol Dial Transplant 19[Suppl 5]: v2O-v26, 2004
22. Nagano N, Nemeth EF: Functional proteins involved in regulation of intracellular Ca2+ for drug development: The extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics. J Pharmacol Sci 97: 355-360, 2005
23. Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Barri YM, Cohen RM, Coburn JW: The calcmimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13: 1017-1024, 2002
24. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA: The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14: 575-583, 2003
25. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW: Cinacalcet HC1, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized double-blind, multicenter study. J Am Soc Nephrol 16: 800-807, 2005
26. Block GA, Martin KJ, de Francisco ALM, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516-1525, 2004
27. Johnson JA, Coons SJ, Ergo A, Szava-Kovats G: Valuation of EuroQoL (EQ-5D) health states in an adult US sample. Pharmacoeconomics 13: 421-433, 1998
28. Hays RD, Kallich JD, Mapes DL, Coons SJ, Amin N, Carter WB: Kidney Disease Quality of Life Short Form (KDQOLSF), Version 1.3: Manual for Use and Scoring. Santa Monica, CA, RAND, P-7994, 1995
29. Martin KJ, Juppner H, Sherrard DJ, Goodman WG, Kaplan MR, Nassar G, Campbell P, Curzi M, Charytan C, McCary LC, Guo MD, Turner SA, Bushinsky DA: First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacaket HCL. Kidney Int 68: 1236-1243, 2005
30. Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, Jadoul M: Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Am J Kidney Dis 44: S34-S38, 2004
31. Souberbielle JC, Boutten A, Carlier MC, Chevanne D, Coumaros G, Lawson-Body E, Massart C, Monge M, Myara J, Parent X, Plouvier E, Houillier P: Inter-method variability in PTH measurement: Implication for the care of CKD patients. Kidney Int 70: 345-350, 2006
32. Moe SM, Chertow GM, Coburn JW: Achieving NKF-K/DOQI bone metabolism and treatment goals with cinacalcet HCI. Kidney Int 67: 760-771, 2005